Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 9.36% is 528% above its 5-year average of -2.19%, near the high end of its 5-year range (-116.87%–21.83%).
14.55% above its 12-month average of 8.17%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-27): 21.83%.
NET PROFIT MARGIN
9.36%
NET PROFIT MARGIN AVG TTM
8.17%
NET PROFIT MARGIN AVG 3Y
-0.33%
NET PROFIT MARGIN AVG 5Y
-2.19%
NET PROFIT MARGIN AVG 10Y
-0.77%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.55%
CURRENT VS 3Y AVG
+2895.13%
CURRENT VS 5Y AVG
+527.65%
CURRENT VS 10Y AVG
+1309.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+3700.00%
vs the sector median at left
Bioventus Inc.
Market Cap
$898.90M
Net Profit Margin
9.36%
TTM Avg
8.17%
3Y Avg
-0.33%
5Y Avg
-2.19%
Market Cap
$912.68M
Net Profit Margin
6.60%
TTM Avg
6.45%
3Y Avg
5.72%
5Y Avg
5.15%
Market Cap
$883.47M
Net Profit Margin
84.23%
TTM Avg
-685.46%
3Y Avg
-487.63%
5Y Avg
-594.40%
Market Cap
$875.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$877.53M
Net Profit Margin
-4994.86%
TTM Avg
-4994.86%
3Y Avg
-4994.86%
5Y Avg
-4994.86%
Market Cap
$927.68M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$930.38M
Net Profit Margin
-64.73%
TTM Avg
-60.89%
3Y Avg
-82.58%
5Y Avg
-82.58%
Market Cap
$932.00M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$934.79M
Net Profit Margin
-384.30%
TTM Avg
-367.92%
3Y Avg
-183.96%
5Y Avg
-122.64%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $898.90M | 9.36% | 8.17% | -0.33% | -2.19% |
| HealthStream, Inc. (HSTM)vs › | $912.68M | 6.60% | 6.45% | 5.72% | 5.15% |
| Arbutus Biopharma Corp (ABUS)vs › | $883.47M | 84.23% | -685.46% | -487.63% | -594.40% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $877.53M | -4994.86% | -4994.86% | -4994.86% | -4994.86% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $927.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| CeriBell, Inc. (CBLL)vs › | $930.38M | -64.73% | -60.89% | -82.58% | -82.58% |
| MoonLake Immunotherapeutics (MLTX)vs › | $932.00M | 0.00% | 0.00% | 0.00% | 0.00% |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | -384.30% | -367.92% | -183.96% | -122.64% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.49M | 116.30% | 67.23% | 16.07% | 4.15% |
Operating Margin
10.6%
Net Profit Margin
9.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-27 | 21.83% |
| 2026-03-28 | 2.36% |
| 2025-12-31 | 9.34% |
| 2025-09-27 | 2.28% |
| 2025-06-28 | 5.05% |
| 2025-03-29 | -2.13% |
| 2024-12-31 | -0.10% |
| 2024-09-28 | -3.47% |
| 2024-06-29 | -16.98% |
| 2024-03-30 | -3.78% |
| 2023-12-31 | -4.50% |
| 2023-09-30 | -6.05% |
| 2023-07-01 | -2.69% |
| 2023-04-01 | -116.87% |
| 2022-12-31 | -25.37% |
| 2022-10-01 | -84.13% |
| 2022-07-02 | -5.17% |
| 2022-04-02 | -9.61% |
| 2021-12-31 | -0.28% |
| 2021-10-02 | -0.98% |
| 2021-07-03 | -3.76% |
| 2021-04-03 | 30.49% |
| 2020-12-31 | 2.82% |
| 2020-09-30 | 9.84% |
| 2020-06-30 | -9.94% |
| 2020-03-28 | 13.92% |
| 2019-12-06 | 5.78% |
| 2019-12-06 | 5.05% |
| 2019-06-29 | -3.58% |
| 2019-03-29 | -2.76% |
| 2016-03-31 | -9.25% |
| 2015-03-31 | -39.39% |
